27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Last week, Axsome Therapeutics Inc's (NASDAQ:AXSM) major depression candidate received the much-awaited FDA approval.
- HC Wainwright notes that the approval comes roughly a year after the original Prescription Drug User Fee Act (PDUFA) decision date.
- Auvelity (dextromethorphan HBr-bupropion HCl, formerly AXS-05) is the first and only rapid-acting oral medicine approved for major depressive disorder with the labeling of statistically significant antidepressant efficacy compared to placebo starting at one week.
- Also Read: What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder.
- The analyst reiterates the Buy rating while raising the price target from $180 to $210.
- As pricing information for Auvelity is awaited, the analyst says that antidepressant agents with good efficacy data have historically experienced robust uptake and that the market remains a segment with high unmet need despite several having several generic agents.
- Boxed warning (specifying suicidal ideation and behaviors) will not be a significant barrier to broad market penetration.
- Price Action: AXSM shares are up 1.70% at $65.56 on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!